62 assets in Neuroblastoma

Therapeutic assets addressing Neuroblastoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
ic9.gd2.car.il-15 t-cells Neuroblastoma	UNC Lineberger Comprehensive Cancer Center	P1	CC (41)
ic9-gd2 t cells Neuroblastoma	Baylor College of Medicine	P1	CC (41)
Iopofosine (¹³¹I) Neuroblastoma	Cellectar Biosciences, Inc.	P1	CC (41)
Lisaftoclax Neuroblastoma	Ascentage Pharma Group Inc.	P1	CC (41)
ly3295668 erbumine Neuroblastoma	Eli Lilly and Company	P1	CC (41)
Mesna Neuroblastoma	St. Jude Children's Research Hospital	P1	CC (41)
Pembrolizumab Neuroblastoma	Seattle Children's Hospital	P1	CC (41)
Second Generation 4-1Bbζ B7H3-Egfrt-Dhfr Neuroblastoma	Seattle Children's Hospital	P1	CC (41)
Second Generation 4-1Bbζ Egfr806-Egfrt Neuroblastoma	Seattle Children's Hospital	P1	CC (41)
Second Generation 4-1Bbζ Egfr806-Egfrt And A Second Generation 4 1Bbζ Cd19-Her2Tg Neuroblastoma	Seattle Children's Hospital	P1	CC (41)
Val-413 Neuroblastoma	Valent Technologies, LLC	P1	CC (41)
124i-humanized 3f8 Neuroblastoma	Memorial Sloan Kettering Cancer Center	N/A	D (30)

Showing 51 to 62 of 62 assets

PreviousPage 2 of 2Next